Unjha Formulations Ltd Upgraded to Hold on Technical and Valuation Improvements

Technical Trends Shift to Bullish Momentum

The most significant catalyst for the rating upgrade is the marked improvement in Unjha Formulations’ technical profile. The technical trend has shifted from mildly bullish to outright bullish, supported by a confluence of positive signals across multiple timeframes. On a weekly basis, the Moving Average Convergence Divergence (MACD) indicator is bullish, while monthly MACD remains mildly bearish, suggesting short-term momentum is gaining strength despite some longer-term caution.

Further reinforcing this positive outlook, Bollinger Bands readings are bullish on both weekly and monthly charts, indicating increased price volatility in an upward direction. Daily moving averages also confirm a bullish stance, with the stock price currently trading at ₹26.12, up 4.94% on the day from a previous close of ₹24.89. The stock’s 52-week high stands at ₹29.50, with a low of ₹17.52, highlighting a strong recovery trajectory over the past year.

Other technical indicators such as the Know Sure Thing (KST) oscillator show bullish momentum weekly but remain bearish monthly, while Dow Theory analysis signals a mildly bullish weekly trend with no clear monthly trend. The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, suggesting the stock is not yet overbought or oversold. Overall, these technical factors collectively underpin the upgrade decision, signalling improving market sentiment and potential for further gains.

Valuation Remains Attractive Amidst Flat Quarterly Performance

Despite flat financial results reported in Q1 FY26-27, Unjha Formulations maintains an attractive valuation profile that supports the Hold rating. The company’s Return on Equity (ROE) stands at a respectable 12.5%, signalling efficient use of shareholder capital. The Price to Book (P/B) ratio is 3, which is considered fair relative to the pharmaceutical sector’s historical averages and peer valuations.

Moreover, the Price/Earnings to Growth (PEG) ratio is exceptionally low at 0.1, indicating that the stock is undervalued relative to its earnings growth potential. Over the past year, profits have surged by 39%, a strong fundamental positive that contrasts with the modest 3.94% stock return during the same period. This disparity suggests that the market has yet to fully price in the company’s earnings growth, providing a valuation cushion for investors.

Unjha Formulations’ market capitalisation remains in the micro-cap segment, with majority shareholding held by non-institutional investors. The stock has outperformed the BSE500 index over multiple time horizons, including 3 years (107.3% return versus 18.87% for BSE500) and 5 years (170.95% versus 37.67%), underscoring its long-term market-beating credentials.

Financial Trend: Mixed Signals from Profit Growth and Debt Servicing

While the company’s operating profits have grown at a modest compound annual growth rate (CAGR) of 6.19% over the last five years, recent quarterly results have been flat, reflecting some near-term operational challenges. The ability to service debt remains a concern, with an average EBIT to interest coverage ratio of just 0.43, indicating weak capacity to meet interest obligations comfortably.

This financial weakness tempers enthusiasm somewhat, but the strong profit growth of 39% over the past year and the company’s ability to generate returns above the Sensex and sector benchmarks provide a counterbalance. Investors should monitor upcoming quarterly results closely to assess whether the flat trend is temporary or indicative of deeper issues.

Technical Upgrade Drives Rating Change

The upgrade from Sell to Hold is primarily attributed to the improved technical grade, which moved from mildly bullish to bullish. This shift reflects a more confident market stance on the stock’s near-term price trajectory. The daily moving averages and weekly MACD bullish signals have been particularly influential, suggesting that momentum is building and that the stock price could continue to appreciate in the coming weeks.

Additionally, the stock’s recent day change of 4.94% and its ability to hold above ₹25.50 intraday lows demonstrate resilience and buying interest. The technical upgrade complements the valuation attractiveness and profit growth, creating a more balanced investment case.

Long-Term Performance and Market Comparison

Unjha Formulations has demonstrated strong long-term returns, significantly outperforming the Sensex over 3, 5, and 10-year periods. The stock’s 3-year return of 107.3% dwarfs the Sensex’s 18.87%, while the 5-year return of 170.95% also far exceeds the Sensex’s 37.67%. Over 10 years, the stock’s return of 168.17% is slightly below the Sensex’s 178.11%, but this is still a commendable performance for a micro-cap pharmaceutical company.

In the near term, the stock has generated a 1-month return of 5.37% compared to the Sensex’s 0.65%, and a 1-week return of 2.43% versus the Sensex’s negative 0.36%. Year-to-date, the stock has gained 4.48% while the Sensex has declined by 9.34%, further highlighting Unjha Formulations’ relative strength in a challenging market environment.

These returns reflect the company’s ability to deliver market-beating performance despite sector headwinds and flat recent quarterly results, reinforcing the rationale for the Hold rating.

Conclusion: Hold Rating Reflects Balanced Outlook

The upgrade of Unjha Formulations Ltd from Sell to Hold is a reflection of improved technical momentum, attractive valuation metrics, and solid long-term returns, balanced against flat recent financial results and weak debt servicing capacity. Investors are advised to view the stock as a cautious buy with potential upside, supported by bullish technical signals and undervaluation relative to earnings growth.

While the company’s financial fundamentals show some weaknesses, particularly in debt coverage and recent flat profit trends, the strong profit growth over the past year and market-beating returns over multiple timeframes provide a compelling case for maintaining exposure at current levels. The Hold rating signals that investors should monitor developments closely but can consider the stock a stable component within a diversified pharmaceutical portfolio.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today